Pfizer gets FDA OK for anti-smoking drug Chantix

Share this article:
The FDA last Thursday approved Pfizer’s anti-smoking pill Chantix (formerly known as Champix) as a treatment to help cigarette smokers quit smoking. Chantix’s main ingredient, varenicline, is a new molecular entity that was granted FDA priority review due to its potential benefits to the public health, the agency said. The drug works by blocking nicotine’s pleasurable effects and reducing the craving and withdrawal symptoms of quitting smoking. Chantix is expected to hit pharmacy shelves in the second half of 2006 with annual global sales estimated to peak at $900 million and only indirect competition from GlaxoSmithKline’s Zyban, an antidepressant also approved to aid in smoking cessation. Euro RSCG Life is responsible for professional advertising duties for Chantix, while Saatchi & Saatchi will handle consumer advertising. Wunderman is working on a Chantix support program.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.